Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) on Monday, plunged -5.73% from the previous trading day, before settling in for the closing price of $19.88. Within the past 52 weeks, ARWR’s price has moved between $17.05 and $36.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -2.87% annually for the last half of the decade. The company achieved an average annual earnings per share of 49.91%. With a float of $116.44 million, this company’s outstanding shares have now reached $124.38 million.
In an organization with 609 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -282.15%, operating margin of -16927.06%, and the pretax margin is -17247.54%.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arrowhead Pharmaceuticals Inc is 6.90%, while institutional ownership is 75.89%. The most recent insider transaction that took place on Jan 23 ’25, was worth 20,139. In this transaction Director of this company sold 959 shares at a rate of $21.00, taking the stock ownership to the 35,781 shares. Before that another transaction happened on Jan 23 ’25, when Company’s Director proposed sale 959 for $20.97, making the entire transaction worth $20,108.
Arrowhead Pharmaceuticals Inc (ARWR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.91% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Arrowhead Pharmaceuticals Inc (ARWR) is currently performing well based on its current performance indicators. A quick ratio of 6.74 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 660.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.00, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -3.36 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.43 million. That was inferior than the volume of 2.65 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 25.47%. Additionally, its Average True Range was 1.10.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 16.42%, which indicates a significant decrease from 19.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.80% in the past 14 days, which was lower than the 66.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.66, while its 200-day Moving Average is $22.66. However, in the short run, Arrowhead Pharmaceuticals Inc’s stock first resistance to watch stands at $19.27. Second resistance stands at $19.80. The third major resistance level sits at $20.17. If the price goes on to break the first support level at $18.38, it is likely to go to the next support level at $18.01. Assuming the price breaks the second support level, the third support level stands at $17.48.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
Market capitalization of the company is 2.34 billion based on 125,073K outstanding shares. Right now, sales total 3,550 K and income totals -599,490 K. The company made 0 K in profit during its latest quarter, and -170,540 K in sales during its previous quarter.
